HER-2 positive + HER-2 overexpression

She received six cycles of neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab. Persistent radiologic abnormalities may represent residual mucin rather than viable tumor cells, underscoring a potential limitation of imaging-based response evaluation. This report provides insight into response interpretation in this rare entity and supports the need for cautious clinical decision-making.

Assessment of the binding efficiency of a fluorescently labeled HER2-specific antibody to the generated cell clones revealed a decrease in fluorescence intensity by 80.6-fold, 33.7-fold, and 2-fold in the SK-BR-3, SK-OV-3, and A549 cell lines, respectively. The generated cell lines with ERBB2 deletion represent a key tool for testing targeted therapeutics and can be utilized in the development of treatment modalities aimed at HER2-overexpressing malignant neoplasms.

These preliminary data might indicate that targeted therapies should be introduced in first line with different strategies depending on molecular alterations, with access to platinum-based palliative systemic anti-cancer treatment being important for patients with IDH1-mutated BTC.

The established liquid biopsy test for serum uPA has potential for accurate diagnosis and staging of patients with HER2+ and borderline-expressing cancers requiring further confirmatory (or rejection) testing.

HER2-positive UC in the institutional IHC-defined cohort and ERBB2-amplified UC in the TCGA cohort were associated with reduced adaptive immune infiltration and attenuated immune-related signaling. These findings support the presence of an immune-cold phenotype in HER2-defined UC and provide hypothesis-generating evidence for further investigation of biomarker-guided combination strategies integrating HER2-targeted therapy with immune checkpoint blockade.

CD24 silencing modulates autophagy and induces apoptosis via Akt/mTOR inhibition, and its combination with trastuzumab exerts potent antitumor effects, offering a promising strategy for HER2 + breast cancer.

This study demonstrates that peptide-functionalized EVs represent a promising tumor-targeted chemotherapeutic platform for HER2-positive breast cancer. By integrating ligand-mediated cellular recognition with EV-based doxorubicin delivery, P51-EVDox activates the ROS/TXNIP signaling pathway, leading to enhanced tumor suppression and apoptosis.

P2, N=19, Active, not recruiting, Nancy Lin, MD | Trial completion date: Dec 2025 --> May 2026

All patients received standard neoadjuvant chemotherapy (FLOT, XELOX, or FOLFOX) followed by curative gastrectomy with D2 lymphadenectomy...HER2 overexpression is associated with poorer pathological response to standard neoadjuvant chemotherapy in gastric adenocarcinoma. These findings highlight the potential need for molecularly tailored perioperative treatment strategies in this subgroup.

Recent advancements in cancer molecular profiling and the Food and Drug Administration's approval of trastuzumab deruxtecan for HER2-positive pan-tumor indications have highlighted the broader relevance of HER2 alterations across diverse cancers...To address this gap, a multidisciplinary panel of Chinese experts has developed a consensus providing comprehensive recommendations on diagnostic strategies, testing methodologies, and clinical applications of HER2 overexpression detection. By establishing a unified framework for HER2 overexpression assessment, this consensus aims to enhance the precision of HER2 testing, optimize patient selection for targeted therapies, and improve clinical outcomes across a wide spectrum of HER2 overexpression malignancies.

Of note, 6/7 cases with HER-2 mutations exhibited limited benefit from treatment with FOLFIRI plus cetuximab with PFS inferior to 8 months. Taken together, these results highlight the need to test HER-2 gene alterations for patients with RAS/BRAF V600 WT, MSS mCRC, who are candidates for anti-epidermal growth factor receptor therapies.

The rHER2 ECD mRNA-LNP effectively circumvents HER2-specific immune tolerance. As a potent and safe platform, it induces robust coordinated humoral and cellular immunity and significantly enhances checkpoint blockade efficacy via the enrichment of TRM cells in the TME, which underscores its promising potential for the treatment of HER2-positive cancers.